PubMed Health⌕ Search

Biomedical subjects

G I Koliaskina

Publications and source records attributed to G I Koliaskina.

At least 19 recordsLinked to original sources
PubMed2004

[Interleukin system in schizophrenics].

Interleukines (IL) levels, mononuclear phagocytes (MP) activity and proliferative T-lymphocytes activity were studied in 6 patients with paranoid (ICD-10 item F20.00) and 20 patients with shift-like (F20.01) types of schizophrenia. Significant (p < 0.05) decrease of MP activity, monocytes-stimulated IL-1 beta production (mostly pronounced in paranoid type) lymphocyte-stimulated IL-2 production (p < 0.05) and proliferate T-lymphocytes activity (p < 0.01) were characteristic of schizophrenia in use of low mitogen doses. A significant increase (p < 0.001) of IL-2 serum concentration was found only in shift-like type. The changes of IL-2 concentration are more frequent in younger patients, aged up to 30 years, with relatively long duration of illness and manifestation stage (over 5 years). An increase of serum IL-2 in the patients was not connected with the changes of soluble IL-2 receptors in the serum as it did not differ from the control values.

Adult↗
PubMed2004

[A change of immune profile of patients with schizophrenia during treatment].

Cellular and humoral immunological parameters have been studied in 59 schizophrenic patients and 38 healthy controls. Immunological indices (CIC, autoantibodies to cardiolipin) were found to be significantly elevated in patients in the acute disease stage before the treatment. After olanzapin therapy, a level of these parameters decreased and did not differ from that of controls. In patients, irrespective of clinical condition and treatment, functional activity of immunocompetent cells (phagocyte activity of neutrophils and monocytes, cytotoxic activity of lymphocytes natural killers, interleukin-2, interleukin-10 and gamma-interferon production), was significantly lower both before the treatment as after therapy, i.e. did not change during the whole study (28 weeks). In responders, a level of IL-1B production was higher than in controls before and during the treatment. In non-responders, it was similar to that in controls before the therapy, and increased during the treatment to a higher level.

Acute Disease↗
PubMed1998

[Correlation between functional activity of lymphocytes in patients with Alzheimer's dementia and their response to therapy].

16 patients with dementia of Alzheimer's type (DAT) were examined. Functional activity of lymphocytes was determined according to proliferating activity of T-lymphocytes, production of Interleukin-1 (IL-1) and estimation of subpopulations of T-leukocytes (T-helpers, T-suppressors). The patients were observed both before and 1-2.5 months after amiridin therapy. Considerable reduction of both IL-1 production and proliferating activity of T-lymphocytes was observed after the treatment in 8 patients of 11. Their cognitive functioning after the therapy was either improved or stable by the moment of repeated observation. It is quite important that initial functional activity of lymphocytes was considerably higher in this group of patients as compared with the age-matched controls. Change for the worse in cognitive functions by the moment of the second examination was accompanied in 5 patients with an increase in IL-1 production as compared to the initial level. It is proposed that high level of IL-1 production by blood lymphocytes may be used as a criterion in selection of DAT patients for amiridin therapy.

Alzheimer Disease↗
PubMed1996

[The immune system characteristics during normal aging and in Alzheimer's disease].

The paper presents a review of data available in the literature and the authors' own findings on age-related physiology and pathology of the immune system. Almost all parameters characterizing the functional activity of the immune system in Alzheimer's disease (AD) were demonstrated to significantly differ from those in the healthy elderly, The magnitude of immunological changes clearly correlated with the severity of dementia in AD patients. A hypothesis of the gradual development of immunological changes in an AD patient in relation to his dementia formation is given.

Adolescent↗
PubMed1996

[The neuroimmune relationships during normal aging and in Alzheimer-type dementias].

Relationships between neurophysiological and immune parameters were studied in normal middle-aged and elderly subjects and in patients with dementia of Alzheimer's type (DAT). The rate of such interaction was minimal in normal aging, in DAT neuroimmune relations increased. The correlation between the immune parameters and the characteristics of components of visual evoked potentials and auditory brain-stem responses suggests that in the middle-aged healthy subjects, a primary role in neuroimmune relations belongs to limbicoreticular structures and to the mesencephalon. In normal aging, the influence of limbicoreticular structures on immune structures decreases. In DAT, the modulation of immune processes by limbicoreticular and thalamocortical structures, as well as the pontobulbar part of the brain stem increases. In middle age and in DAT, persons with different functional brain asymmetry (as estimated from electrophysiological criteria) have different lymphocytic functional activities and rates of neuroimmune interactions.

Adult↗
PubMed1996

[Bispecific monoclonal antibodies: the isolation and study of their antigen-binding properties].

Bifunctional antibodies (bABs) having a double specificity to alpha-endorphin (alpha-END) and horseradish peroxidase (HRP) were produced by hybridoma technology. The antibodies constituted about 28-29% of all immunologically active IgG secreted by hybrid hybridoma (quadroma). The quadroma was isolated by fusion of two murine hybridomas (anti-HRP and anti-alpha-END) with distinct phenotypes: double mutant AMD(R)/NAT(S) and its wild type. To produce the double mutant phenotype, an actinomycin D-resistant (AMD(R)) mouse myeloma was used to initiate one of the parental hybridomas. bABs were purified from quadroma culture medium and ascitic fluids by sequential HRP-sepharose and alpha-END-sepharose affinity chromatography. With radioimmunoassay, the affinity of the individual anti-alpha-END combining sites of bABs was shown to be identical to that of parental monoclonal antibodies. Binding to the second antigen (HRP) did not affect the binding of bABs to alpha-END. bABs proved to be efficient for the determination of endorphins and their precursor proopiomelanocortin in immunohistology and immunoblotting.

Animals↗
PubMed1996

[The functional activity of the lymphocyte subpopulations in patients with schizophrenia and schizoaffective psychosis].

The functional activity of natural killer (NK) and of T-helper (TH) lymphocytes was examined both in 19 patients with schizophrenia and in 6 patients with schizoaffective psychosis as well as in 93 control individuals. The patients were examined both before the treatment and two months after it. The cytotoxic level of NK lymphocytes was considerably decreased in all the patients before the treatment. The TH activity was decreased in 8 of 17 schizophrenic patients and in 1 of 4 schizoaffective patients observed during the acute period. The increase of cytotoxic NK activity was seen in patients with schizoaffective psychosis after the treatment while such alterations in schizophrenic patients were absent. The TH activity changed neither in schizophrenic nor in schizoaffective patients after the treatment.

Adolescent↗
PubMed1995

[Changes in the immunological parameters in Alzheimer's disease: their relation to disease severity].

The peculiarities of the immune system in patients with Alzheimer's dementia (AD) and their relations with some clinical parameters were investigated. 21 patients with AD aged 51-70 and 16 age-matched healthy subjects were included in this study. The following parameters were examined: 1) total lymphocyte numbers, 2) the functional activity of T- and B-lymphocytes under conditions of stimulation by nonspecific mitogens phytohemagglutinin (PHA) and pokeweed mitogen (PWM) and 3) the production of interleukin-1 (IL-1) and interleukin-2 (IL-2). A statistically significant decrease (p < 0.01) in lymphocyte number and significant increase of proliferative activity of T-lymphocytes, stimulated by PHA (when the small mitogen doses in the range of 1.25-2.5 mg/ml were used) were found in patients with moderate and severe dementia (p < 0.05, p < 0.01). No significant changes of lymphocyte proliferative activity were detected in patients with mild dementia. Some tendency for higher IL-1 production was found in AD patients, but it was not statistically significant. No changes of functional activity of B-cells and of production of IL-2 in AD patients were found in comparison with the control group.

Aged↗
PubMed1995

[Neuroimmune interactions in normal aging and in Alzheimer disease].

The study was undertaken to examine nerve-immune processes and the specific visual and limbic-reticular-cortical systems by analysing visual evoked potentials (VEP), as well as nerve-immune relationships in 21 patients aged 62.2ë1.3 years who had Alzheimer's disease and in 15 healthy individuals of the same age. AD patients were found to have lower lymphocyte count, enhanced proliferative activity of T lymphocytes and to tend to have increased production of interleukin (IL-1) as compared to that in healthy individuals. In AD, latent periods of late EVP components are higher than normal age-specific ones. The relationship between VEP and immunity parameters differ in normal ageing and AD. In health, there is a negative correlation between the latencies of N1, P2, N2 VEP components and the lymphocyte count and between the amplitude of a N1 VEP component and the production of IL-1. There is a prevalent correlation of immune parameters with VEP parameters in the right hemisphere. In AD, the higher proliferative activity of T lymphocytes is associated with more prolonged latent periods of N3 VEP components, suggesting that there are abnormal changes in the limbic-reticular-cortical systems of the brain.

Aging↗
PubMed1988

[Use of levamisole in the combined therapy of patients with slowly progressing juvenile schizophrenia].

Immunomodulating drug Levamisole was studied as a component in the combined treatment of juvenile slow progredient schizophrenia. Apart from normalizing the immune parameters, the drug improved the patients' clinical conditions. Most prominent was its clinical effect in patients with immune system sensitive to the drug. The patient's condition ameliorated in relation with the features of his initial state. Treating the patients with depressive-asthenic states has yielded the best results. Weaker was the effect on patients with obsessive-phobic disorders. The least curable were senesto-hypochondriac and dysmorphophobic disorders with sensitive delusions of relation.

Adolescent↗
PubMed1988

[Imipramine antibodies in endogenous depression in young people].

The drug antibodies were radioimmunologically detected in 58.3% of depressive patients treated with Imipramine. A group of patients with the antibodies permanently present either proved fully resistant or showed a minor effect. A group with antibodies arising just at the start of the treatment displayed either complete remission or substantial improvement. Antibodies were not found in patients exhibiting full recovery or considerable improvement.

Adult↗
PubMed1987

[Use of the immunomodulator levamisole in the complex treatment of juvenile schizophrenics with an unfavorable course].

The authors investigated the effect of the immunostimulant levamisole on the immunological reactivity of schizophrenics and the resultant decrease in the therapeutic resistance of these patients toward psychotropic therapy. Thirteen patients with juvenile malignant continuously progressive schizophrenia were studied, using a double blind design of examination. The number of suppressor T-cells in patients treated with levamisole increased from 16.6% to 22.8% (p less than 0.001) which was not observed in patients on placebo. It has been demonstrated that the immunological parameters in patients with juvenile malignant continually progressive schizophrenia can be fully recovered. Yet, the changes observed in the clinical picture were heterogeneous and unremarkable. The experimental findings suggest that the use of levamisole may be more effective in patients with less progressive forms of the disease.

Adult↗
PubMed1985

[Anti-thymocyte antibodies in schizophrenia: clinico-immunologic and genetic correlations].

The blood levels of anti-thymocytic IgG, IgM and IgA were studied in schizophrenics, their relatives and normal donors. The schizophrenic patients and their relatives had significantly elevated levels of IgG and IgM. The increased level of IgG in schizophrenic patients may be considered as a reflection of the pathological process or, perhaps, as a response to disease exacerbation. A high concentration of IgM is implicated in hereditary liability to schizophrenia being a significant although insufficient component of the patient's ability to develop the disease.

Adult↗
PubMed1985

[Genetic analysis of antithymocyte activity in schizophrenia].

Immunologic changes in schizophrenic psychoses were examined by different methods of genetic analysis. The cytotoxic test and the method of fluorescent antibodies showed an increase in the antithymocytic activity (ATA) of the blood serum. A high index of the coefficient of a genetic correlation between elevated blood levels of ATA and the genetic component of liability to the disease indicates that genetic factors partially involved in the general structure of hereditary predisposition to schizophrenic psychoses participate in the determination of interindividual differences with regard to blood ATA levels. The data obtained suggest that the observed antithymocytic activity of the blood serum was due to at least 2 types of antibodies with different affinity to thymocytes.

Adult↗